FORE Biotherapeutics — Valuation, Funding & Investors

Recent changes

Jul 7, 2026Jul 7, 2026Raised $67.4M Series D-2 BusinessWire
Jul 7, 2026Jul 7, 2026FORE Biotherapeutics Raises $67.4M to Push BRAF Cancer Drug Pulse story

Funding History

1 event · sources dated per row

Date	Event	Amount	Valuation	Investors	Source
Jul 7, 2026	Series D-2	$67.4M	—	SR OneMedicxiSymBiosis	Pulse story

Latest Pulse

Jul 7, 2026FORE Biotherapeutics Raises $67.4M to Push BRAF Cancer DrugFORE Biotherapeutics closed an upsized $67.4 million Series D-2 extension, bringing its total Series D-2 to $110 million, to fund late-stage development of plixorafenib toward a targeted 2027 FDA submission for BRAF-mutated tumors.→

Coverage Timeline

newest first

Jul 7, 2026FUNDINGFORE Biotherapeutics Raises $67.4M to Push BRAF Cancer Drug$67.4M (Series D-2 extension)→

All Coverage

FUNDING· Jul 7, 2026

FORE Biotherapeutics Raises $67.4M to Push BRAF Cancer Drug

FUNDING$67.4M (Series D-2 extension)

FORE Biotherapeutics Raises $67.4M to Push BRAF Cancer Drug

FORE Biotherapeutics closed an upsized $67.4 million Series D-2 extension, bringing its total Series D-2 to $110 million, to fund late-stage development of plixorafenib toward a targeted 2027 FDA submission for BRAF-mutated tumors.

Jul 7, 2026

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics

Sources & methodologyshow

Where these figures come from

BusinessWireprimary source1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction